Metformin and breast cancer risk: a meta-analysis and critical literature review

被引:159
作者
Col, Nananda F. [1 ,2 ]
Ochs, Leslie [2 ]
Springmann, Vicky [3 ]
Aragaki, Aaron K. [4 ]
Chlebowski, Rowan T. [5 ]
机构
[1] Shared Decis Making Resources, Georgetown, ME 04548 USA
[2] Univ New England, Coll Osteopath Med, Biddeford, ME USA
[3] Univ Montreal, Montreal, PQ, Canada
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
关键词
Metformin; Breast cancer; Meta-analyses; Literature review; DIABETES-MELLITUS; INCIDENT CANCER; MANAGEMENT; OUTCOMES; COHORT; DRUGS; WOMEN;
D O I
10.1007/s10549-012-2170-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Observational studies have suggested that metformin decreases the incidence of several common cancers. However, findings regarding breast cancer have been mixed. In order to explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching PubMed, Cochrane Library, and Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms." When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR and performed sensitivity analyses on duration of metformin use (> or a parts per thousand currency sign3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). From a total of 443 citations, 18 full-text articles were considered, and seven independent studies were included. All were observational (four cohort and three case control). Our combined OR of all seven studies was 0.83 (0.71-0.97). Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin use (OR = 0.75. 95 % CI 0.62, 0.91) or among studies that began observing their cohort before 1997 (OR = 0.68. 95 % CI 0.55-0.084). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Our analyses support a protective effect of metformin on breast cancer risk among postmenopausal women with diabetes. Clinical trials are needed for definitive determination of the role of metformin in breast cancer risk reduction.
引用
收藏
页码:639 / 646
页数:8
相关论文
共 44 条
  • [1] Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
    Alimova, Irina N.
    Liu, Bolin
    Fan, Zeying
    Edgerton, Susan M.
    Dillon, Thomas
    Lind, Stuart E.
    Thor, Ann D.
    [J]. CELL CYCLE, 2009, 8 (06) : 909 - 915
  • [2] [Anonymous], DIABETES RES CLIN PR
  • [3] [Anonymous], ANN ONCOL
  • [4] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) : 520 - 529
  • [5] Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
    Bayraktar, Soley
    Hernadez-Aya, Leonel F.
    Lei, Xiudong
    Meric-Bernstam, Funda
    Litton, Jennifer K.
    Hsu, Limin
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana M.
    [J]. CANCER, 2012, 118 (05) : 1202 - 1211
  • [6] Ben-Sahra I, 2011, CANC RES
  • [7] Does use of metformin protect against cancer in Type 2 diabetes mellitus?
    Bo, S.
    Benso, A.
    Durazzo, M.
    Ghigo, E.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2012, 35 (02) : 231 - 235
  • [8] Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
    Bodmer, Michael
    Meier, Christian
    Krahenbuehl, Stephan
    Jick, Susan S.
    Meier, Christoph R.
    [J]. DIABETES CARE, 2010, 33 (06) : 1304 - 1308
  • [9] Bonanni B, 2012, J CLIN ONCOL
  • [10] Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case-Control Study in Denmark
    Bosco, Jaclyn Lee Fong
    Antonsen, Sussie
    Sorensen, Henrik Toft
    Pedersen, Lars
    Lash, Timothy L.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (01) : 101 - 111